file1
,
file2
, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*
).
Wildcard '?' to blanket only one character works too.Historiographs |
Grand Totals: LCS 17722, GCS 106366, CR 136943 Collection span: 1963 - 2012 | |
Word(i) List (4568) Word count: 24159, All words count: 34321 |
# | Word | Recs | TLCS | TGCS |
---|---|---|---|---|
601 | VIRUS | 12 | 29 | 851 |
602 | ANTI-HUMAN | 6 | 28 | 158 |
603 | ANURIA | 1 | 28 | 54 |
604 | AUGMENTED | 2 | 28 | 63 |
605 | CIRCULATING | 12 | 28 | 596 |
606 | CONCEPTS | 11 | 28 | 256 |
607 | DUCTOPENIC | 3 | 28 | 118 |
608 | ENDOTHELIAL | 8 | 28 | 394 |
609 | HYPOREACTIVITY | 4 | 28 | 79 |
610 | IMMEDIATE | 1 | 28 | 54 |
611 | OLIGURIA | 1 | 28 | 54 |
612 | ORAL | 13 | 28 | 255 |
613 | PANCREATIC-ISLET | 4 | 28 | 393 |
614 | PATIENT | 18 | 28 | 215 |
615 | QUANTITATION | 4 | 28 | 111 |
616 | TECHNIQUE | 12 | 28 | 68 |
617 | ANTI-DONOR | 2 | 27 | 90 |
618 | BALANCE | 4 | 27 | 191 |
619 | BONE-MARROW-DERIVED | 2 | 27 | 127 |
620 | DOUBLE-BLIND | 5 | 27 | 208 |
621 | HEPATITIS | 18 | 27 | 589 |
622 | HEPATOTOXICITY | 1 | 27 | 244 |
623 | INTERACTIONS | 8 | 27 | 422 |
624 | ORIGIN | 13 | 27 | 439 |
625 | PHENOTYPE | 3 | 27 | 83 |
626 | PRELIMINARY | 10 | 27 | 245 |
627 | SCIATIC | 2 | 27 | 197 |
628 | WHOLE-BLOOD | 7 | 27 | 161 |
629 | BEINGS | 2 | 26 | 137 |
630 | CD95L | 3 | 26 | 179 |
# | Word | Recs | TLCS | TGCS |
631 | CONTRIBUTE | 3 | 26 | 140 |
632 | DECADE | 5 | 26 | 332 |
633 | DISORDERS | 12 | 26 | 334 |
634 | EXPERIENCES | 5 | 26 | 116 |
635 | FAS | 2 | 26 | 183 |
636 | MINOR | 6 | 26 | 50 |
637 | PHASE | 6 | 26 | 209 |
638 | PRACTICAL | 6 | 26 | 132 |
639 | PULMONARY | 10 | 26 | 339 |
640 | RATIO | 2 | 26 | 134 |
641 | SUPPRESSED | 2 | 26 | 147 |
642 | THORACIC-DUCT | 4 | 26 | 86 |
643 | UNIFYING | 1 | 26 | 41 |
644 | ADJUNCTIVE | 2 | 25 | 106 |
645 | ANTIGENS | 16 | 25 | 302 |
646 | ERA | 10 | 25 | 331 |
647 | FIBROUS | 1 | 25 | 187 |
648 | GINGIVA | 2 | 25 | 190 |
649 | HISTOINCOMPATIBILITY | 1 | 25 | 82 |
650 | MINIMAL | 5 | 25 | 154 |
651 | MONKEYS | 11 | 25 | 164 |
652 | OBSERVATION | 1 | 25 | 144 |
653 | ORGAN-SPECIFIC | 2 | 25 | 81 |
654 | RELATION | 8 | 25 | 157 |
655 | RISK | 16 | 25 | 560 |
656 | SIDE-EFFECT | 1 | 25 | 187 |
657 | SUCCESS | 4 | 25 | 56 |
658 | TIME | 6 | 25 | 107 |
659 | UREMIC | 9 | 25 | 522 |
660 | ALEMTUZUMAB | 7 | 24 | 203 |
# | Word | Recs | TLCS | TGCS |
661 | COMPARTMENTALIZATION | 1 | 24 | 27 |
662 | COUNTER-REGULATORY | 1 | 24 | 167 |
663 | CYTOCHROME | 4 | 24 | 261 |
664 | DETERRENTS | 1 | 24 | 127 |
665 | DIFFERENTIAL | 8 | 24 | 275 |
666 | DOSAGE | 7 | 24 | 240 |
667 | GROUP | 4 | 24 | 193 |
668 | HAMSTER-TO-RAT | 7 | 24 | 176 |
669 | HEMOPOIETIC | 3 | 24 | 113 |
670 | HOMOTRANSPLANTS | 5 | 24 | 154 |
671 | HYBRIDIZATION | 3 | 24 | 137 |
672 | IMPORTANCE | 6 | 24 | 189 |
673 | INSTITUTION | 2 | 24 | 435 |
674 | MOLECULE | 9 | 24 | 185 |
675 | NEEDED | 2 | 24 | 48 |
676 | NONLYMPHOID | 1 | 24 | 27 |
677 | OKT3 | 6 | 24 | 153 |
678 | PITTSBURGH | 3 | 24 | 73 |
679 | PROVIDE | 1 | 24 | 167 |
680 | RESTORATION | 1 | 24 | 38 |
681 | SIGNALS | 2 | 24 | 167 |
682 | SOLID-ORGAN | 5 | 24 | 54 |
683 | SPLEEN-DERIVED | 1 | 24 | 38 |
684 | STABLE | 7 | 24 | 461 |
685 | UROLOGICAL | 5 | 24 | 421 |
686 | XENOGENEIC | 11 | 24 | 601 |
687 | ANTIBODIES | 17 | 23 | 142 |
688 | ANTIGEN-PRESENTING | 2 | 23 | 68 |
689 | BIOTRANSFORMATION | 1 | 23 | 299 |
690 | CAMPATH | 2 | 23 | 124 |
# | Word | Recs | TLCS | TGCS |
691 | CONTINUING | 2 | 23 | 48 |
692 | CONTRIBUTIONS | 3 | 23 | 75 |
693 | CONTROL | 7 | 23 | 238 |
694 | CYTOCHROME-P-450 | 2 | 23 | 304 |
695 | DISRUPTION | 1 | 23 | 68 |
696 | DOSING | 4 | 23 | 198 |
697 | FEATURES | 9 | 23 | 479 |
698 | FOLLOWED | 3 | 23 | 221 |
699 | HORSE | 9 | 23 | 207 |
700 | IMMUNOFLUORESCENT | 2 | 23 | 182 |
701 | INTERMEDIATE-TERM | 2 | 23 | 118 |
702 | LOCAL | 8 | 23 | 364 |
703 | MORPHOLOGICAL | 4 | 23 | 221 |
704 | OBLITERATIVE | 2 | 23 | 68 |
705 | POTENCY | 2 | 23 | 203 |
706 | SELECTED | 3 | 23 | 90 |
707 | TOPICS | 2 | 23 | 83 |
708 | TRANSDUCTION | 4 | 23 | 274 |
709 | TRANSPLANTED | 23 | 23 | 841 |
710 | URINARY | 11 | 23 | 317 |
711 | USES | 6 | 23 | 75 |
712 | ANALYTICAL | 4 | 22 | 137 |
713 | CYA | 6 | 22 | 134 |
714 | DISEASES | 11 | 22 | 345 |
715 | FEASIBLE | 2 | 22 | 80 |
716 | FK506-BINDING | 3 | 22 | 325 |
717 | INCREASED | 15 | 22 | 251 |
718 | METHODS | 8 | 22 | 130 |
719 | MITIGATES | 1 | 22 | 151 |
720 | PREDNISOLONE | 9 | 22 | 138 |
# | Word | Recs | TLCS | TGCS |
721 | PROBE | 4 | 22 | 260 |
722 | PRODUCED | 7 | 22 | 120 |
723 | PROTOCOLS | 7 | 22 | 94 |
724 | RENAL-TRANSPLANTS | 8 | 22 | 145 |
725 | SEROTYPING | 1 | 22 | 41 |
726 | STRATEGY | 8 | 22 | 183 |
727 | TERM | 5 | 22 | 79 |
728 | VASCULAR | 13 | 22 | 374 |
729 | BILATERAL | 6 | 21 | 161 |
730 | BIOPSIES | 9 | 21 | 269 |
731 | CLINIC | 8 | 21 | 150 |
732 | COURSE | 6 | 21 | 180 |
733 | DEVELOPING | 6 | 21 | 221 |
734 | DRAINAGE | 9 | 21 | 131 |
735 | EXENTERATION | 1 | 21 | 228 |
736 | GLUCOSE-METABOLISM | 4 | 21 | 86 |
737 | GLYCEMIA | 1 | 21 | 30 |
738 | HEPATOCYTES | 10 | 21 | 103 |
739 | HUMORAL | 13 | 21 | 198 |
740 | IMMUNOBIOLOGY | 7 | 21 | 3601 |
741 | IMPAIRMENT | 6 | 21 | 195 |
742 | INBRED | 6 | 21 | 135 |
743 | INJECTION | 18 | 21 | 125 |
744 | LANDMARKS | 3 | 21 | 43 |
745 | MAY | 3 | 21 | 35 |
746 | NEED | 3 | 21 | 70 |
747 | NEUROIMMUNOPHILIN | 5 | 21 | 184 |
748 | OWN | 1 | 21 | 47 |
749 | PANCREATITIS | 9 | 21 | 187 |
750 | PATHOGENETIC | 1 | 21 | 71 |
# | Word | Recs | TLCS | TGCS |
751 | PEDIATRIC-PATIENTS | 4 | 21 | 147 |
752 | PERIPHERAL-NERVE | 1 | 21 | 104 |
753 | PORCINE | 9 | 21 | 583 |
754 | PREDISPOSING | 2 | 21 | 164 |
755 | PRESERVATION | 6 | 21 | 213 |
756 | QUESTION | 1 | 21 | 50 |
757 | REFRACTORY | 5 | 21 | 118 |
758 | RELEASE | 7 | 21 | 238 |
759 | RISKS | 5 | 21 | 399 |
760 | SALVAGE | 3 | 21 | 102 |
761 | SCIATIC-NERVE | 1 | 21 | 200 |
762 | STANDARD | 3 | 21 | 47 |
763 | SUBSET | 3 | 21 | 114 |
764 | TRIALOMANIA | 1 | 21 | 46 |
765 | TWELVE | 1 | 21 | 75 |
766 | UPPER | 5 | 21 | 260 |
767 | ADVANCES | 10 | 20 | 188 |
768 | AUTOIMMUNE | 18 | 20 | 408 |
769 | BODY | 7 | 20 | 572 |
770 | COLD | 2 | 20 | 120 |
771 | DETERMINE | 2 | 20 | 48 |
772 | ENHANCEMENT | 3 | 20 | 70 |
773 | EXTRAHEPATIC | 2 | 20 | 78 |
774 | FEMORAL | 2 | 20 | 44 |
775 | HEART-LUNG | 2 | 20 | 52 |
776 | HOURS | 5 | 20 | 165 |
777 | INITIAL | 10 | 20 | 312 |
778 | INSULIN-SECRETION | 2 | 20 | 64 |
779 | INTRATHYMIC | 11 | 20 | 61 |
780 | INVOLVEMENT | 6 | 20 | 275 |
# | Word | Recs | TLCS | TGCS |
781 | ISCHEMIA | 11 | 20 | 356 |
782 | KILLER | 7 | 20 | 153 |
783 | MAINTAINS | 2 | 20 | 38 |
784 | MATURE | 3 | 20 | 426 |
785 | MICROSCOPIC | 4 | 20 | 70 |
786 | MODIFIED | 8 | 20 | 109 |
787 | MOLECULAR-CLONING | 1 | 20 | 294 |
788 | OVEREXPRESSION | 1 | 20 | 294 |
789 | PORTAL | 15 | 20 | 205 |
790 | POSSIBILITY | 1 | 20 | 96 |
791 | POTENTIATES | 3 | 20 | 177 |
792 | PRETRANSPLANT | 6 | 20 | 124 |
793 | PROCEDURE | 3 | 20 | 327 |
794 | SPLENECTOMY | 12 | 20 | 218 |
795 | URINE | 2 | 20 | 94 |
796 | WELL-TOLERATED | 1 | 20 | 96 |
797 | YEAR | 7 | 20 | 212 |
798 | ALLOANTIGEN | 4 | 19 | 88 |
799 | ANTI-LYMPHOCYTIC | 5 | 19 | 111 |
800 | AZATHIOPRINE-ANTILYMPHOCYTE | 1 | 19 | 192 |